HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
-
BUSINESS Biogen Eyes 2020 Aducanumab Filing in Japan Too, Nailing Down Re-Dosing Study Details
December 19, 2019
-
REGULATORY FY2020 Drug Price Revision to Shed 110 Billion Yen in Central Govt Spending
December 18, 2019
-
REGULATORY Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
-
REGULATORY Chuikyo Settles on “Third Price Revision” for Expansion of Comparator PMP Deduction Rule
December 16, 2019
-
BUSINESS Keytruda on Track to Become a US$10 Billion Drug in 2019
December 13, 2019
-
REGULATORY 6 Drugs Face Generic Entries, 2 Firms to Roll Out Symbicort Copies: December Listing
December 12, 2019
-
REGULATORY Xolair Adds Pollen Allergy Use in Japan after 19-Day Delay
December 12, 2019
-
REGULATORY “Third Price Revision” Eyed for Expansion of Comparator PMP Deduction Rule
December 11, 2019
-
BUSINESS Healios Poised to Go into the Black with Sakigake-Designated MultiStem, Revs Up Universal Cell Biz
December 10, 2019
-
REGULATORY Metformin Manufacturers Ordered to Test for Potential Carcinogen Contamination
December 10, 2019
-
REGULATORY Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
December 9, 2019
-
REGULATORY Big 4 Wholesalers Faced Wrath of FTC for Allocating Priority Drug Categories before Bidding
December 6, 2019
-
COMMENTARY Course of Govt’s “All-Generation” Social Security Reform Could Impact Pharma
December 5, 2019
-
REGULATORY Average NHI-Market Price Gap at 8.0%, Suspected Bid-Rigging Data Excluded: Chuikyo
December 4, 2019
-
BUSINESS With Audentes Buyout, Astellas Poised to Position “Genetic Regulation” as 5th Biz Pillar
December 4, 2019
-
BUSINESS Astellas to Buy Gene Therapy Player Audentes for US$3 Billion
December 3, 2019
-
REGULATORY Causal Link between Eisai’s Epilepsy Drug and Trial Death Can’t Be Ruled Out: MHLW
December 2, 2019
-
BUSINESS Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
-
BUSINESS 10-Plus Japan Drug Makers Up FY2019 Guidance on Bullish New Drugs, Mainstays: Tally
November 29, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
